Extracorporeal Membrane Oxygenation Therapy

Extracorporeal membrane oxygenation (ECMO) provides temporary cardiopulmonary support when conventional ventilation or circulation support is insufficient. Venovenous ECMO primarily supports severe respiratory failure, while venoarterial ECMO supports cardiac, circulatory, or combined cardiopulmonary failure. Its use depends on patient selection, reversible disease, institutional capability, trained personnel, and access to intensive care, perfusion, surgical, and rehabilitation services. The field is shaped by clinical protocols, referral pathways, equipment interoperability, infection prevention, anticoagulation management, and the need to balance rapid deployment with highly specialized care.

The ECMO landscape has moved toward more standardized eligibility assessment, multidisciplinary decision-making, and structured escalation and weaning protocols. Experience from severe respiratory viral disease reinforced the importance of regional referral networks, mobile retrieval teams, surge planning, and staff cross-training. Clinical programs increasingly emphasize early referral, complication prevention, rehabilitation, shared decision-making, and post-discharge follow-up rather than treating cannulation as an isolated intervention. Broader adoption is still constrained by workforce requirements, uneven access to high-acuity transport, consumable availability, and variation in reporting practices.

Artificial intelligence can support ECMO care by identifying patterns in flow, pressure, oxygenation, anticoagulation, laboratory results, and ventilator data. Potential applications include early warning for circuit malfunction, bleeding or thrombosis risk, patient deterioration, and readiness for weaning. Predictive tools may also improve staffing prioritization, documentation, and retrospective quality review. Their safe use requires representative clinical data, transparent validation, cybersecurity controls, human oversight, and prospective evaluation across different devices and patient populations. AI should complement, not replace, bedside expertise in cannulation, troubleshooting, and end-of-life decisions.

North America generally combines advanced tertiary-care infrastructure, established extracorporeal programs, and mature critical-care transport capabilities, while access remains uneven across hospitals and geographic areas. Europe benefits from specialized centers and cross-border clinical collaboration, with implementation influenced by national health systems and European Union regulatory requirements. Asia-Pacific includes highly capable programs alongside substantial variation in equipment access, workforce depth, and rural reach. Latin America is strengthening referral networks and specialist capacity but faces financing, transport, and supply-chain constraints. The Middle East is investing in advanced critical care, with capability concentrated in major centers. Africa continues to face limited access to specialized ECMO teams, infrastructure, and follow-up services, making referral partnerships and training especially important.

ASEAN members face wide differences in tertiary-care capacity, workforce distribution, and cross-border referral infrastructure, making shared training and regional protocols valuable. BRICS countries combine large and diverse health systems, with priorities spanning domestic manufacturing, specialist training, equitable access, and standardized outcomes reporting. The European Union emphasizes coordinated standards, patient mobility, data governance, and resilient supply chains. G7 health systems generally focus on quality improvement, workforce sustainability, emergency preparedness, and evidence-based patient selection. GCC countries are expanding advanced hospital capability while concentrating expertise in major referral centers. NATO members place added emphasis on interoperability, critical-care logistics, trauma readiness, and continuity of care during emergencies.

Australia supports ECMO through concentrated specialist services and retrieval pathways, with geography making transport coordination important. Brazil and Mexico must address regional inequality, referral delays, and uneven availability of trained teams. Canada and the United States have established advanced-care centers, but distance, staffing, and payer or system-level access differences remain relevant. China and India are expanding specialist capacity across large populations while working through regional variation in training and infrastructure. Japan and South Korea bring strong hospital capabilities and aging-population considerations to program planning. France, Germany, Italy, Spain, and the United Kingdom have substantial tertiary-care expertise, with national or regional approaches to referral, commissioning, quality measurement, and workforce organization. Russia’s ECMO capability is shaped by geographic scale, concentration of specialist resources, and supply-chain resilience. Across all countries, outcomes depend on timely referral, experienced teams, standardized protocols, and robust post-ECMO rehabilitation.

Leaders should define evidence-based referral and eligibility pathways, maintain clear escalation and futility-review processes, and use multidisciplinary governance for high-risk cases. Programs should build formal relationships with referring hospitals, transport services, rehabilitation providers, and regional authorities; simulation training and competency assessment should cover cannulation, circuit emergencies, anticoagulation, infection prevention, and decannulation. Quality systems should track clinically meaningful outcomes, complications, time to referral, functional recovery, and patient-reported experience using consistent definitions. Investment decisions should also consider device interoperability, consumable resilience, cybersecurity, data standards, and equitable access. AI pilots should begin with narrowly defined clinical or operational use cases and require prospective safety monitoring before wider deployment.

This executive summary uses a structured qualitative synthesis of verified information from recognized clinical guidance, peer-reviewed ECMO literature, registry and outcomes reporting, public health and regulatory materials, and health-system documentation. Findings were organized around therapy modes, patient selection, complications, workforce, referral models, technology, regional infrastructure, and policy conditions. Regional, group, and country observations were compared for recurring evidence on capability, access, governance, and implementation barriers. Claims were limited to established or directly supported patterns; no market estimates, market shares, forecasts, or company-specific assessments were used. Because ECMO practice changes rapidly, local protocols and current regulatory requirements should be checked before operational decisions.

ECMO remains a resource-intensive rescue and bridge therapy whose value depends on selecting appropriate patients and delivering coordinated care before, during, and after support. The strongest strategic opportunities lie in regionalized referral, workforce development, standardized measurement, resilient supply chains, rehabilitation, and responsible use of digital tools. Differences among regions, international groups, and countries mean that implementation should be adapted to local epidemiology, infrastructure, financing, transport, and governance. Leaders who combine clinical rigor with equitable network design and transparent outcome review will be better positioned to improve safety, recovery, and system resilience.